Background - The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 to 310 mg/dL) with triglycerides ≤2.5 mmol/L (220 mg/dL) to simvastatin 20 to 40 mg or placebo once daily. Over the median follow-up period of 5.4 years, one or more major coronary events (MCEs) occurred in 622 (28%) of the 2223 patients in the placebo group and 431 (19%) of the 2221 patients in the simvastatin group (34% risk reduction, P
CITATION STYLE
Pedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., … Cook, T. J. (1998). Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97(15), 1453–1460. https://doi.org/10.1161/01.CIR.97.15.1453
Mendeley helps you to discover research relevant for your work.